ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    PhEED
Previous Study | Return to List | Next Study

Pharyngeal Electrical Stimulation Evaluation for Dysphagia After Stroke (PhEED)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03358810
Recruitment Status : Recruiting
First Posted : December 2, 2017
Last Update Posted : April 9, 2018
Sponsor:
Collaborators:
Regulatory and Clinical Research Institute Inc
Cytel Inc.
Information provided by (Responsible Party):
Phagenesis Ltd.

Brief Summary:
This is a randomized, sham-controlled, patient masked, outcome assessor-blinded study to assess a Pharyngeal Electrical Stimulation (PES) Catheter for treatment of oropharyngeal dysphagia following a stroke.

Condition or disease Intervention/treatment Phase
Dysphagia Following Cerebral Infarction Device: PES Not Applicable

Detailed Description:

Randomization will be stratified at each site in a 1:1 fashion. All patients will have the Phagenyx® Catheter placed prior to randomization, and will receive either an active treatment of Pharyngeal Electrical Stimulation (PES) or a sham treatment performed by a health care professional (HCP) that is un-blinded to treatment assignment. All other speech pathology standard dysphagia care will be provided by a speech language pathologist (SLP) that is blinded to treatment assignment. Administration of all protocol-specific assessments will be conducted by personnel blinded to treatment assignment.

The study will follow an adaptive group sequential design with unblinded sample size re-assessment. To ensure 180 evaluable patients with 7-day data and assuming a 20% dropout rate, 225 patients will be enrolled initially. An interim analysis for futility will occur after the first 60 patients complete their 7-day visits and another interim analysis will be performed for efficacy and futility after 120 patients complete their 7-day visits. The total sample size may be increased up to 338 patients after the second interim analysis to ensure up to 270 evaluable patients. Up to 15 investigational centers across the US and possibly Europe will participate in this study. The enrollment period is expected to be approximately 24 months and patient participation will last for approximately 11 weeks. Patients will be assessed at the following intervals: baseline, 48 hours, 7 days, 14 days or at discharge, whichever is first, and 11 weeks after completion of the study treatments.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 270 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Care Provider)
Primary Purpose: Treatment
Official Title: Pharyngeal Electrical Stimulation Evaluation for Dysphagia After Stroke
Actual Study Start Date : March 31, 2018
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : March 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Active group
patients randomized to receive active PES
Device: PES
The PES system is a two-part neurostimulation system. It is composed of a durable component called the Base Station and the single-use sterile disposable Phagenyx® Catheter. The Base Station acts as the user interface and provides the means to generate, optimize and monitor the delivery of electrical stimulation.
Other Name: Pharyngeal Electrical Stimulation

Sham Comparator: Sham treatmment
Patients randomized to sham will not receive any PES.
Device: PES
The PES system is a two-part neurostimulation system. It is composed of a durable component called the Base Station and the single-use sterile disposable Phagenyx® Catheter. The Base Station acts as the user interface and provides the means to generate, optimize and monitor the delivery of electrical stimulation.
Other Name: Pharyngeal Electrical Stimulation




Primary Outcome Measures :
  1. To evaluate the efficacy of treatment in reducing the severity of unsafe swallows based on PAS(Penetration Aspiration Scale)of each swallow during VFSS [ Time Frame: 48 hours post final treatment ]

    VFSS (Vidoeflouroscopic Swallow Study) Swallowing safety of a bolus of thin and nectar consistency determined by a videofluoroscopic swallowing study.The PAS provides a scoring mechanism for airway closure and clearance during the VFSS. The PAS is a validated 8-point scale that measures penetration and aspiration. Scores are determined primarily by the depth to which material passes into the airway.

    1. Material does not enter airway
    2. Material enters the airway, remains above the vocal folds, and is ejected
    3. Material remains above the vocal folds, and is not ejected from airway
    4. Material contacts the vocal folds, and is ejected
    5. Material contacts the vocal folds, and is not ejected
    6. Material passes below the vocal folds , and is ejected out airway
    7. Material passes below the vocal folds, and is not ejected from trachea
    8. Material enters the airway , and no effort is made to eject it


Secondary Outcome Measures :
  1. To evaluate the efficacy of Phagenyx® treatment in improving nutritional management [ Time Frame: 11 weeks post final treatment ]

    Nutritional management changes will be evaluated via:

    Time from baseline to removal of enteral feeding (i.e., removal of NG tube or PEG or transition to oral feeding, or first diet upgrade,Functional Oral Intake Scale (FOIS) at 7 days, 14 days or discharge, whichever is first, and 11 weeks




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ 18 and ≤ 90 years.
  • Acute ischemic or hemorrhagic cerebral stroke within 7-28 days of baseline VFSS.
  • Score of 0 or 1 on NIHSS question 1a, Level of Consciousness.
  • Moderate to severe dysphagia (PAS >4) on baseline VFSS (Baseline VFSS must meet the threshold criteria of demonstrating a PAS of ≥ 4, in three of the six boli (5 mL/1 tsp/bolus), during swallowing "thin liquid" barium media as assessed by the clinical staff administering the VFSS.).
  • Willing and able to have the Phagenyx® Catheter placed transnasally.
  • Willing and able to provide informed consent.
  • Stated willingness to comply with all study procedures and availability for the duration of the study.

Exclusion Criteria:

  • Brainstem stroke.
  • Evidence of traumatic brain injury or subarachnoid hemorrhage.
  • Other known brain abnormalities documented by history and/or imaging (e.g., tumor, abnormal white matter, inflammatory neuropathy, myelin delamination, hydrocephalus).
  • Dysphagia from conditions other than stroke.
  • Pre-stroke history of swallowing complaints or treatment or history of diseases known to be associated with swallowing problems (other neurological, head and neck cancer.
  • Distorted oropharyngeal anatomy (e.g., pharyngeal pouch, major pharyngeal surgery or head /neck surgery)
  • Currently being treatment for pneumonia.
  • Mute, global aphasia; no usable speech or auditory comprehension (scores 3 on NIHSS question 9, Best Language)
  • NIHSS score of >25
  • Presence of a tracheostomy
  • Any active implanted device (e.g., cochlear implant, ICD)
  • Any progressive neurological disorder (e.g., Parkinson's Disease, Multiple Sclerosis)
  • Cognitive impairment that prevents compliance with protocol-specific instructions and assessments
  • Unstable cardiopulmonary condition, i.e., not on maintenance therapy.
  • Currently participating in another investigational study
  • Pregnant or planning to become pregnant while participating in the clinical study -Known Allergy to oral radiographic contrast media (specifically barium) -

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03358810


Contacts
Contact: Sr. Director Clinical US +49 161 820 4525 nadine.juran@phagenesis.com

Locations
United States, Illinois
Marianjoy Recruiting
Wheaton, Illinois, United States, 60187
Contact: Physiatrist PI         
Sponsors and Collaborators
Phagenesis Ltd.
Regulatory and Clinical Research Institute Inc
Cytel Inc.

Responsible Party: Phagenesis Ltd.
ClinicalTrials.gov Identifier: NCT03358810     History of Changes
Other Study ID Numbers: AHE-05
First Posted: December 2, 2017    Key Record Dates
Last Update Posted: April 9, 2018
Last Verified: December 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Infarction
Deglutition Disorders
Cerebral Infarction
Ischemia
Pathologic Processes
Necrosis
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Pharyngeal Diseases
Otorhinolaryngologic Diseases
Brain Infarction
Brain Ischemia
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Stroke
Vascular Diseases
Cardiovascular Diseases